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Background: The aim of this study was to determine the risk factors for conversion from a normal to either a low or high
ankle-brachial index (ABI).
Methods: Participants in the Multi-Ethnic Study of Atherosclerosis who had two separate measurements of the ABI over
a 3-year time period were assessed.
Results: At baseline, the mean age was 62 years and 50% were women, 28% African American, 12% Chinese, 22% Hispanic
and 38% non-Hispanic White. Of the 5514 participants with a baseline ABI between 0.90 and 1.40, 89 (1.6%) had an
ABI < 0.90 (“low ABI group”) and 71 (1.3%) had an ABI > 1.40 (“high ABI group”) 3 years later. On multivariable
analysis, the odds for having progressed into the low ABI group were significantly increased for higher baseline age,
hypertension, diabetes, greater pack-years of cigarette smoking, and homocysteine levels. The odds for progression into
the high ABI group were increased for male gender and higher body mass index. Compared with non-Hispanic Whites,
African Americans had a significantly higher odds for progression to the low ABI group (odds ratio [OR]: 2.24, 95%
confidence interval [CI]: 1.29-3.88) while having a reduced odds for progression to the high ABI group (OR: 0.50, 95%
CI: 0.24-1.00). Neither Chinese nor Hispanic ethnicity was significantly associated with progression to either ABI group.
Conclusions: The risk factors for progression to a low or high ABI were distinct and African Americans were at increased
risk for progression to a low ABI but at decreased risk for progression into the high ABI group. (J Vasc Surg 2009;50:
1049-56.)The ankle-brachial index (ABI) is a valid1 and repro-
ducible2,3 method for detecting peripheral arterial disease
(PAD). Since it is simple, inexpensive and noninvasive, the
ABI is suitable for screening asymptomatic individuals
and in community-based studies. Using an ABI value
typically less than 0.90 as the criterion, many clinical and
population-based studies have determined the prevalence
of PAD.4-8 In these studies and compared with Whites,
African Americans have repeatedly been shown to have a
higher prevalence of PAD while Hispanic and Chinese
Americans typically have prevalences similar to Whites.4,7,8
Moreover, this excess of PAD in African Americans appears
independent of both traditional and novel cardiovascular
disease (CVD) risk factors.9,10
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doi:10.1016/j.jvs.2009.05.061Recent evidence supports the importance of higher
values of the ABI due in part to medial artery calcification as
a marker of peripheral vascular disease.11 That is, individu-
als with an ABI  1.40 have higher levels of certain CVD
risk factors,12,13 subclinical atherosclerosis14,15 and risks
for both incident total12 and CVD-related16 mortality
while also having impaired quality of life in certain areas.13
Compared with a low ABI, studies on the prevalence of a
“high ABI” aremore limited and therefore, the associations
of ethnicity with a “high ABI” are not as well characterized.
From a clinical perspective, if the initial ABI is normal,
it is important to understand the incidence of and risk
factors for progression to an abnormal value. However,
there are few studies on determinants of changes in the ABI
and we are unaware of any studies that evaluated the risk in
multiple ethnic groups. Accordingly, the aim of this study
was to determine the risk factors for longitudinal changes in
the ABI to abnormal levels in the Multi-Ethnic Study of
Atherosclerosis (MESA), including traditional and novel
cardiovascular disease risk factors and an emphasis on
ethnicity.
METHODS
Subjects. Details about the MESA study design have
been published elsewhere.17 In brief, between July 2000
and August 2002, 6814 men and women who identified
themselves as White, African American, Hispanic, or Chi-
nese, were 45 to 84-years-old and were free of clinically
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participated in the baseline examination. Individuals with a
history of physician-diagnosed heart attack, angina, heart
failure, stroke, or transient ischemic attack (TIA), or having
undergone an invasive procedure for cardiovascular disease
were excluded from participation. The participants enrolled
at baseline were eligible to participate in three subsequent
study examinations occurring approximately every 2 years
and referred to as clinic visits 2, 3, and 4. At clinic visit 3,
subjects underwent repeat testing for the ankle-brachial
index.
Participants were recruited from the following six com-
munities: Baltimore City and Baltimore County, Maryland;
Chicago, Ill; Forsyth County, NC; Los Angeles County,
Calif Northern Manhattan and the Bronx, NY; and St.
Paul, Minn. Each field site recruited from locally available
sources, which included lists of residents, lists of dwellings,
and telephone exchanges. The institutional review boards
at all participating centers approved the study and all par-
ticipants gave informed written consent.
Data collection. At the baseline examination and at
visit 3, standardized questionnaires were used to obtain
demographic information and level of education, annual
household income, smoking history, and medication usage
for high blood pressure, high cholesterol, or diabetes.
Cigarette smoking was calculated in pack-years and also
defined as current, former, or never. Height and weight
were measured with participants wearing light clothing and
no shoes. Body mass index (BMI) was calculated as weight
in kilograms divided by height in meters squared. Resting
blood pressure was measured three times in seated partici-
pants with a Dinamap model Pro 100 automated oscillo-
metric sphygmomanometer (Critikon, Tampa, Fla). The
average of the last two measurements was used in the
analysis. Hypertension was defined as systolic blood pres-
sure 140 mm Hg, diastolic blood pressure 90 mm Hg,
or current use of an antihypertensive medication.
Laboratory. At the baseline examination and at visit
3, blood was collected after a 12-hour fast and stored at
70°C. Total and high-density lipoprotein (HDL) choles-
terol, triglycerides, glucose and creatinine were measured
as previously reported17 low-density lipoprotein (LDL)
cholesterol was calculated by the Friedewald equation.18
Dyslipidemia was defined as a total-cholesterol/HDL-
cholesterol ratio  5.0 or use of cholesterol reducing
medication. Diabetes was defined as fasting glucose 126
mg/dL or use of hypoglycemic medication. Impaired fast-
ing glucose was defined as glucose 100 to 125 mg/dL.19
The estimated glomerular filtration rate (eGFR) was calcu-
lated using the modified of diet in renal disease (MDRD)
study formula.20
Using baseline blood samples, measurements of the
following classes of non-lipid biomarkers were conducted
at either at the Laboratory for Clinical Biochemistry Re-
search (University of Vermont, Burlington, Vt) or the
Biochemical Genetics Clinical Laboratory at Fairview-
University Medical Center (Minneapolis, Minn): inflam-
mation (high-sensitivity plasma C-reactive protein, fibrin-ogen, interleukin-6), insulin concentration (fasting insulin)
and hemostasis/fibrinolysis (factor VIII coagulant activity,
plasmin-antiplasmin complex, D-dimer) as well as homo-
cysteine.
Ankle-brachial index protocol. At the baseline ex-
amination and clinic visit 3, systolic blood pressure mea-
surements for calculation of the ABI were obtained using a
hand-held Doppler instrument with a 5-mHz probe (Nico-
let Vascular, Golden, Colo). In brief, systolic blood pres-
sures were measured in the bilateral brachial, dorsalis pedis,
and posterior tibial arteries. Brachial artery pressures were
averaged to obtain the ABI denominator. When the two
brachial artery pressures differed by 10mmHg or more, the
highest brachial artery pressure was used as the denomina-
tor.21 For each lower extremity, the ABI numerator used
was the highest pressure (dorsalis pedis or posterior tibial)
from that leg. The lower of the right and left ABI values was
used as the index ABI for that subject. In the analyses of
prospective changes, the ABIs from the same leg were
compared from baseline to visit 3. We defined progression
to a “low ABI” as going from an ABI between 0.90 and
1.40 (a normal ABI) at baseline to an ABI 0.90 at visit 3.
Similarly, we defined progression to a “high ABI” as going
from a normal ABI at baseline to an ABI  1.40 at visit 3.
Individuals with an incompressible ankle artery at either
study visit were excluded from the study due to the inability
to calculate the change in ABI for the affected vessel. A
subset of 384 MESA participants had replicate ABI mea-
surements at visit 3. The overall intraclass correlation coef-
ficient (ICC) from these measurements was 0.93 while the
intra-technician ICC was 0.95 and the inter-technician
ICC was 0.92.
Statistical analysis. Non-normally distributed vari-
ables were log transformed to achieve normality. Age, sex,
and race-adjusted means and percentages by ABI group at
follow-up were computed using analysis of covariance. The
P values from these analyses compared those progressing
into the low or high groups to those maintaining an ABI in
the normal range. To estimate the associations of CVD risk
factors and ethnicity with ABI progression (high or low),
separate logistic regression models were constructed to
determine odds ratios (ORs) and 95% confidence intervals
(CI). The outcome for one set of models was progression
to the low ABI group while the outcome for the other was
progression into the high ABI group. We first analyzed the
associations adjusting for age and sex. We then adjusted for
BMI, hypertension dyslipidemia, pack-years of smoking,
diabetes, and family history of heart disease. Associations
between changes in the ABI and changes in these same risk
factors between visit 1 and visit 3 was modeled by adding
the “change” variables to the baseline variables in multiva-
riable logistic regression models. The associations of non-
lipid biomarkers with ABI progression were evaluated by
separately adding each biomarker to the fully adjusted
models. Those significantly associated with progression
into the low or high ABI groups were retained in the final
multivariable models. All analysis was done using Stata,
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P value of .05 was considered statistically significant.
RESULTS
Baseline characteristics of the MESA cohort stratified
by race are provided in Table I. For all racial groups, the
mean age was approximately 62 years and roughly 50%
were women. African Americans had the largest body mass
index while Chinese Americans had the smallest. African
Americans also had the highest estimated glomerular filtra-
tion rate and prevalence of hypertension while Caucasians
had the highest prevalence of dyslipidemia. Hispanic and
African Americans had a similar prevalence of diabetes
mellitus. Although African Americans also had the highest
prevalence of current smokers, Caucasians had the highest
amount of cigarette smoking whenmeasured in pack-years.
African Americans had the highest levels of homocysteine,
C-reactive protein, interleukin-6, fibrinogen, D-dimer, fac-
tor VIII, and plasmin-antiplasmin. Finally, the overall mean
baseline ABI was 1.11, which was lowest in African Amer-
icans (1.07), highest in Hispanic Americans (1.12), and
intermediate for non-Hispanic Whites and Chinese Amer-
icans (1.11 and 1.10, respectively).
The mean time between visit 1 and visit 3 ABI mea-
surements was 3.2 (SD 0.32) years. Nine-hundred and
twenty-seven participants did not have their ABI measured
at visit 3; 867 of these were because the participant did not
Table I. Cohort characteristics by ethnicity: The multi-eth
Characteristic
African Ameri
(N  1894)
Age (y)a 62.1 (10.0)
Female† 1050 (55.4)
Body mass index (kg/m2)a 30.2 (5.9)
Glomerular filtration rate (mL/min/1.73 m2) 86.4 (19.3)
Glucose (mg/dL)a 107.2 (32.7)
Insulin (mU/L)a 7.4 (6.7)
Diabetesb 369 (19.6)
Systolic blood pressure (mm Hg)a 132 (22)
Diastolic blood pressure (mm Hg)a 74 (10.2)
Hypertensionb 1127 (59.5)
Total cholesterol (mg/dL)a 190 (36.3)
HDL cholesterol (mg/dL)a 52 (12.7)
LDL cholesterol (mg/dL)a 117 (33.0)
Triglycerides (mg/dL)a 105 (69.0)
Dyslipidemiab 312 (16.5)
Cigarette smoking (pack/y)a 11.9 (19.5)
Current smokerb 338 (18.0)
Homocysteine (mol/L)a 9.7 (4.1)
C-reactive protein (mg/L)c 2.53 (1.08-5.
Interleukin-6 (pg/mL)a 1.7 (1.3)
Fibrinogen (mg/dL)a 361 (80)
D-dimer (g/mL)a 0.45 (1.0)
Factor VIII (%)a 178 (74.5)
Plasmin-antiplasmin (nM)a 5.2 (2.5)
HDL, High-density lipoprotein; LDL, low-density lipoprotein.
aMean (SD).
bFrequency (%).
cMedian (interquartile range).attend visit 3. This group was similar to those who did havean ABI measured at visit 3 with respect to gender distribu-
tion, baseline ABI, body mass index, pack-years of cigarette
smoking, homocysteine, cholesterol medication use, and
serum creatinine. Conversely, the non-visit three partici-
pants were older and had lower prevalence of hypertension
and diabetes.
Correlations between risk factors and changes in the
continuous ABI value from visit 1 to visit 3 were all very
modest (r  0.10). With adjustment for age, sex, and
ethnicity, there were essentially no risk factor associations
for large (0.05/y) increases or decreases in the ABI
except for cigarette smoking. Compared with those who
did not exhibit a large increase or decrease in the ABI from
visit 1 to visit 3, those who had a large decline had a higher
prevalence of current smoking (17.0% vs 10.1%, P 0.03)
while those who had a large increase in the ABI had a lower
prevalence of current smoking (6.9% vs 10.1%, P  0.01).
Of the 5514 MESA participants with a baseline ABI
between 0.90 and 1.40, 89 (1.6%) had an ABI  0.90 and
71 (1.3%) had an ABI 1.40 at visit 3. Table II shows the
age, sex, and race-adjusted baseline risk factor distributions
for those whose ABI changed from normal to (1) less than
or equal to 0.90 (“low ABI group”), (2) greater than or
equal to 1.40 (“high ABI group”), or (3) remained be-
tween 0.90 and 1.40 (“normal ABI group”). The mean
age, sex, and ethnicity adjusted baseline ABI value for the
low ABI group was 1.02. Compared with those in the
study of atherosclerosis
Chinese
(N  803)
Hispanic
(N  1493)
Caucasian
(N  2624)
62.3 (10.3) 61.3 (10.3) 62.6 (10.2)
413 (51.4) 775 (51.9) 1363 (51.9)
24.0 (3.3) 29.4 (5.1) 27.7 (5.1)
82.3 (16.7) 83.3 (18.4) 75.9 (17.0)
106.1 (28.8) 110.7 (39.7) 98.4 (22.1)
6.1 (5.7) 8.1 (6.1) 6.0 (4.5)
122 (15.2) 291 (19.5) 189 (7.2)
125 (21.6) 127 (21.9) 124 (20.4)
72 (10.3) 72 (10.1) 70 (10.0)
301 (37.5) 618 (41.4) 1012 (38.6)
193 (31.8) 198 (37.5) 196 (35.1)
50 (12.7) 48 (13.1) 52 (15.7)
115 (29.0) 120 (32.9) 117 (30.1)
143 (84.8) 157 (101) 133 (90.2)
118 (14.7) 211 (14.1) 460 (17.5)
4.9 (14.2) 7.7 (16.5) 15.1 (27.6)
45 (5.6) 203 (13.6) 301 (11.5)
9.0 (2.9) 9.1 (3.2) 9.3 (4.0)
0.87 (0.47-1.79) 2.45 (1.15-4.91) 1.75 (0.26-4.02)
1.2 (1.0) 1.7 (1.2) 1.5 (1.2)
329 (60) 359 (75) 334 (70)
0.28 (0.43) 0.37 (0.82) 0.35 (0.86)
158 (57.0) 162 (63.4) 157 (64.6)
4.1 (1.4) 4.6 (2.0) 4.8 (2.2)nic
can
71)normal ABI group and after adjustment for age, sex, and
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low ABI group included a lower baseline ABI but a higher
fasting blood glucose, cholesterol, triglycerides, pack-years
smoking, and homocysteine, as well as higher prevalences
of hypertension and current smoking. The mean age, sex,
and ethnicity adjusted baseline ABI value for the high ABI
group was 1.19. Compared with those in the normal ABI
Table II. Age, sex, and race-adjusted baseline risk factor l
multi-ethnic study of atherosclerosis
Risk factor
Low ABI (0.9)
[N  89]
Age (y)a 68.3 (9.9)
Gender (female)b 50 (56.2)
Baseline ABIa 1.02 (0.08)
Body mass index (kg/m2)a 28.2 (5.0)
Creatinine (mg/dL)a 0.95 (0.17)
Glomerular filtration rate (mL/min/1.76 m2) 80.8 (22.6)
Glucose (mg/dL)a 112.3 (27.9)
Insulin (mU/L)a 7.3 (5.3)
Diabetesb 19 (21.3)
Hypertensionb 61 (68.5)
HDL cholesterol (mg/dL)a 49.2 (13.5)
LDL cholesterol (mg/dL)a 119.2 (31.2)
VLDL cholesterol (mg/dL)a 5.4 (5.5)
Triglycerides (mg/dL)a 155 (85)
Dyslipidemiab 17 (19.1)
Total cholesterol (mg/dL)a 198 (35)
Cigarette smoking (pack/y)a 17.9 (21.2)
Current smokerb 18 (20.2)
Homocysteine (mol/L)a 10.2 (3.3)
C-reactive protein (mg/L)c 2.44
Interleukin-6 (mg/dL)a 1.55 (1.1)
Fibrinogen (mg/dL)a 351 (68)
D-dimer (g/mL)a 0.37 (0.74)
Factor VIII (%)a 163 (64)
Plasmin-antiplasmin (nM)a 4.4 (1.9)
ABI, Ankle-brachial index; HDL, high-density lipoprotein; LDL, low-densi
aMean (SD).
bFrequency (%).
cMedian (interquartile range).
Table III. Risk factor associations for progression to an an
Variable
ABI  0.90
Odds ratio 95% CI
Age (10 y) 1.91 1.47-2.48
Gender (male) 0.74 0.46-1.18
BMI (3 units) 0.97 0.83-1.09
Hypertension 1.73 1.03-2.89
Dyslipidemia 0.72 0.40-1.31
Smoking (10 pack/y) 1.09 1.03-1.15
Diabetes 1.82 1.04-3.19
Family history of CHD 1.28 0.81-2.03
Homocysteine (10 units) 1.53 1.10-2.11
New hypertension 2.46 1.11-5.44
New dyslipidemia 1.74 1.02-2.97
BMI, Body mass index; CHD, coronary heart disease.group, the significant baseline risk factors for progressinginto the high ABI group included a higher baseline ABI,
body mass index, and insulin but a lower HDL cholesterol.
Baseline smoking was less prevalent among those who
progressed into the high ABI group.
In a logistic regression model containing age, sex,
ethnicity, body mass index, hypertension, diabetes, dyslip-
idemia, smoking, and family history of CHD (Table III),
by category of ABI progression over 3 years: The
ABI status at year 3 P values
ormal ABI (0.91-1.39)
[N  5354]
High ABI (1.4)
[N  71]
Low vs
normal
High vs
normal
61.2 (9.9) 60.0 (10.0) .0005 .33
2,824 (52.8) 26 (36.6) .56 .01
1.11 (0.08) 1.19 (0.08) .01 .01
28.2 (5.0) 29.8 (5.0) 1.00 .01
0.95 (0.17) 0.95 (0.17) .72 .97
81.3 (16.9) 80.4 (14.0) .29 .66
102.7 (27.8) 102.2 (28.0) .01 .89
6.7 (5.3) 8.0 (5.3) .30 .05
652 (15.3) 5 (7.0) .12 .25
2242 (41.1) 22 (31.0) .02 .17
51.2 (13.5) 47.9 (13.5) .16 .04
117.3 (31.0) 116.4 (31.3) .58 .81
3.8 (5.4) 4.8 (5.5) .01 .16
130 (85) 135 (85) .01 .62
848 (15.0) 7 (9.9) .75 .19
194 (35) 190 (35) .29 .27
10.5 (21.1) 7.9 (21.2) .01 .30
645 (10.4) 3 (4.2) .01 .05
9.1 (3.3) 9.2 (3.3) .01 .88
2.23 2.49 .65 .12
1.47 (1.1) 1.47 (1.1) .50 .99
343 (68) 352 (69) .27 .27
0.34 (0.74) 0.33 (0.75) .74 .90
161 (63) 162 (64) .75 .84
4.7 (1.9) 4.4 (1.9) .20 .24
protein; VLDL, very low-intensity lipoprotein.
brachial index (ABI) less than 0.90 or greater than 1.40
ABI  1.40
P value Odds ratio 95% CI P value
.01 1.07 0.82-1.41 .60
.20 1.78 1.06-3.00 .03
.58 1.25 1.09-1.45 .01
.04 0.61 0.34-1.08 .09
.29 0.56 0.24-1.32 .19
.01 0.95 0.83-1.09 .45
.04 0.62 0.24-1.61 .33
.29 1.00 0.60-1.67 .99
.01 — — —
0.03 — — —
0.04 — — —evels
N
ty lipokle-the odds for having progressed into the lowABI group were
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(OR: 1.07, 95% CI: 1.04-1.10), hypertension (OR: 1.75,
95% CI: 1.05-2.91), diabetes (OR: 1.81, 95% CI: 1.83-
3.17), and pack-years of cigarette smoking (10 pack-year
increment) (OR: 1.09, 95% CI: 1.04-1.15). Statin use was
associated with a nonstatistically significant reduction pro-
gression to a low ABI (OR: 0.64, 95%CI: 0.34-1.21). [The
results for ethnicity are provided in the text below]. When
the 3-year changes in the CVD risk factors were included,
both new hypertension (OR: 2.46, 95% CI: 1.11-5.44) and
new dyslipidemia (OR: 1.74, 95% CI: 1.02-2.07) were
associated with progression into the low ABI group. Using
the same CVD risk factor variables listed above, the odds of
progression into the high ABI group were only significant
for male gender (OR: 1.78, 95% CI: 1.06-3.00), baseline
body mass index (1-unit increment) (OR: 1.08, 95% CI:
1.03-1.13). Statin use was associated with a significant
reduction in the odds for progression to a high ABI (OR
0.29, 95% CI: 0.09-0.94). None of the 3-year changes in
the CVD risk factor variables were significantly association
with progression into the high ABI group.
Of the nontraditional CVD risk factors (eg, CRP, fi-
brinogen, etc), only higher homocysteine (1 mol/L)
(1.04, 1.01-1.08) was significantly associated with progres-
sion to the low ABI group while there were no significant
associations between any of the nonlipid biomarkers and
progression to the high ABI group (results not shown).
Using logistic modeling similar to that described above
and with adjustment for age and sex and compared with
Fig 1. Ethnicity and the odds of progressing into the low ankle-
brachial index (ABI) group* over 3 years: The Multi-Ethnic Study
of Atherosclerosis.
*Defined as an ABI 0.90 (non-HispanicWhite Americans are the
reference group).
Model 1 – Adjusted for age and sex.
Model 2 – Adjusted for age, sex, body mass index, hypertension,
diabetes, smoking, and dyslipidemia.
Model 3 – Adjusted for age, sex, body mass index, hypertension,
diabetes, smoking, dyslipidemia, new hypertension, and new dys-
lipidemia.
Model 4 – Adjusted for age, sex, body mass index, hypertension,
diabetes, smoking, dyslipidemia, family history of cardiovascular
disease (CVD) new hypertension, new dyslipidemia, and homocys-
teine.non-Hispanic Whites, African Americans had a nearly 2.5-fold higher odds (P  .01) for progressing to the low ABI
group (Fig 1). This association was modestly attenuated
with further adjustment for bodymass index, hypertension,
diabetes, dyslipidemia, and smoking (OR: 2.20, 95% CI:
1.27-3.82) and new hypertension and hypercholesterol-
emia (OR: 2.02, 95% CI: 1.21-3.37) but not when homo-
cysteine was added to the model (OR: 2.06, 95% CI:
1.23-3.44). Compared with non-Hispanic Whites, the risk
of progression to the low ABI group was not different for
Chinese or Hispanics.
Fig 2 shows the associations between ethnicity and
progressing to the high ABI group. With adjustment for
age and sex and compared with non-Hispanic Whites,
African Americans had a lower odds for progressing to the
high ABI group (OR: 0.53, 95% CI: 0.28-1.03) that was
slightly accentuated with adjustment for the traditional
CVD risk factors (OR: 0.50, 95% CI: 0.24-1.00). Chinese
and Hispanic participants were not at a different risk than
non-Hispanic whites for progression to the high ABI
group.
We conducted the same logistic regression analyses as
those described above but utilizing ABI cut-points of 1.00
and 1.30. The results for these analyses were similar but, in
general, the magnitudes of the associations were not as
large as for those with ABI cut-points of 0.90 and 1.40.
Also, there is controversy about whether analyses involving
change variables as outcomes should include adjustment
for the baseline values.22,23 In sensitivity analyses, we ran
multivariable logistic models that added the baseline ABI
value to the final logistic models described above. This
resulted in modest attenuation of the associations between
the variables studied and progression into either the low or
high ABI groups. Exceptions were the association between
male gender and progression into the high ABI group
diminishing dramatically to unity, and a reversal of the
positive, albeit nonsignificant, coefficient for women for
Fig 2. Race specific odds for progressing into the high ankle-
brachial index (ABI) group* over 3 years: The Multi-Ethnic Study
of Atherosclerosis.
*Defined as an ABI 1.40 (non-HispanicWhite Americans are the
reference group).
Model 1 – Adjusted for age and sex.
Model 2 – Adjusted for age, sex, body mass index, hypertension,
diabetes, smoking, and dyslipidemia.progression to a low ABI. These results suggest that after
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der was not significantly related to ABI change.
DISCUSSION
In this prospective study of a population-based multi-
ethnic cohort, increasing age, hypertension, diabetes, cig-
arette smoking, and homocysteine were significantly asso-
ciated with progression to an ABI  0.90, while male
gender and higher body mass index were significantly asso-
ciated progression to an ABI  1.40. Additionally and
compared with non-Hispanic Whites, African American
ethnicity was significantly associated with an elevated odds for
progression from a normal ABI to an ABI  0.90, indepen-
dent of the levels of other risk factors. Conversely, the odds for
converting from a normal ABI to an ABI  1.40 among
African Americans was lower than among Whites but this
difference was not statistically significant. These results
suggest that there are factors that we did not measure that
might predispose African Americans to developing a low
ABI or protect them from developing a high ABI. Alterna-
tively, there may be other, yet untested risk factors that may
explain the differential associations between different ABI
and racial groups.
Physiologically, at least 50% stenosis in the lower ex-
tremities is required to cause a sufficient reduction in blood
flow to reduce blood pressure distal to an obstruction.24
Although there are other potential etiologies for luminal
stenosis in the lower extremities, the predominant cause for
significant flow-limiting disease is the accumulation of ath-
erosclerosis.25,26 Conversely, the physiologic mechanism
resulting in an ABI above the normal range is assumed to be
mechanical rigidity of the arteries in the lower extremities
due to reduced arterial compliance or medial artery calcifi-
cation.11,27 We postulate that in a state of “arterial equilib-
rium”, these two processes could progress equally resulting
in a stable ABI values over time in most people. Conversely,
when one of the processes is predominant in a given indi-
vidual, the ABI value would change in favor of that process.
In this context it is important that African Americans in
our study were found to have a significantly increased risk
for developing a “low ABI”, while at the same time, poten-
tially having reduced risk for increasing the ABI above 1.40.
Due to potential intrinsic differences in the elasticity and
geometry of arteries in the lower extremities, African Amer-
icans have lower ABI values than those of other ethnic
groups28 and are therefore more likely to have an ABI less
than 0.90. Additionally, and forgoing differences in the
rates of subclinical stenosis between different ethnic
groups,29 the findings of increased odds for progressing
below an ABI of 0.90, along with a probable reduction in
the odds for progressing above an ABI greater than 1.40,
suggests that African Americans, compared with non-
Hispanic Whites, may be more predisposed to developing
significant atherosclerosis in the lower extremity resulting
in flow-limiting stenosis. The alternative explanation is that
in African Americans the progression of atherosclerosis is
similar to that in non-Hispanic Whites but the progression
of arterial rigidity is slower than in this ethnic group. Thisseems unlikely, however, since African Americans have
been found to have lower arterial compliance than non-
Hispanic Whites.30
Compared with African Americans, Hispanic Ameri-
cans in our study had similar age and sex-adjusted preva-
lences of baseline diabetes and dyslipidemia, as well as levels
of body mass index and essentially all of the non-lipid
biomarkers. However, Hispanic Americans did not have an
increased risk for changing their ABIs beyond either ABI
threshold utilized in this study. Using the conceptual
framework provided above, potential explanations for this
result include no change in the extent of both atheroscle-
rosis and arterial rigidity over the 3-year follow-up. Given
that the natural history of atherosclerosis is for progression
(rather than stability or regression) to more extensive dis-
ease,31 it follows that the arterial rigidity would have to
progress at a similar rate to maintain the “equilibrium”
between these two process seen in this ethnic group. This is
supported by the finding of Hispanic Americans having
high risk factor levels for both atherosclerosis (dyslipide-
mia, hypertension) and arterial rigidity (body mass index)
than non-HispanicWhites. Of note, African Americans also
had high levels of risk factors for both atherosclerosis and
arterial rigidity. Therefore, why was this ethnic group pre-
disposed to a lower ABI while Hispanics were not? A
possible explanation is that African Americans had higher
levels of other atherosclerotic risk factors, such as hyperten-
sion and cigarette smoking, than Hispanics and therefore
the “balance” was tipped towards this disease process.
We do not believe that the lack of association between
Hispanic ethnicity and changes in the ABI is due to an
inability of the ABI to detect PAD in this ethnic group.
Rather, we believe it is the excess of diabetes in Hispanics,
compared with other ethnic groups. Specifically, diabetes
is a risk factor for both atherosclerosis and arterial rigidity,
and there is a strong concordance between atherosclerosis
and arterial rigidity. That is, among those who have stiff
arteries, a high proportion will also have PAD.32 However,
95% of those who have diabetes do not have stiff arteries
and the finding of both conditions concomitantly is there-
fore a small proportion of Hispanics. Therefore, we believe
the misclassification in our study is small.
Although not statistically significant, compared with
non-Hispanic Whites, Chinese Americans in our study had
reduced odds for both progression to the low and high
ABI. Specifically, Chinese Americans had a clinically rele-
vant odds ratio of approximately 0.60 for progression to
either ABI group. Importantly, the magnitude of the odds
for progressing into the high ABI group was comparable to
that found in African Americans indicating that the lack of
significance was due to the smaller sample size in the
Chinese. Physiologically, these results suggest that Chinese
Americans may be similar to Hispanic Americans in that
they are not predisposed to developing more atherosclero-
sis than arterial rigidity and vice versa or perhaps less
predisposed to either.
Individuals with diabetes have been shown to have a
higher prevalence of stiff arteries and medial artery calcifi-
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significant risk factor for progressing to a high ABI. It is
therefore curious that diabetes was not a significant risk
factor for progressing to a high ABI in our study. We
believe a plausible explanation for this finding is that our
study was conducted in the context of a multi-ethnic co-
hort. In this regard and compared with non-Hispanic
Whites, African and Hispanic American ethnicities were
associated with a reduced risk for progressing to a high ABI
and both had over twice the prevalence of diabetes as
non-Hispanic Whites. Additionally, diabetes is a potent risk
factor for the development and progression of atheroscle-
rosis, as well as PAD.33,34 Therefore, the effects of diabetes
on arterial pathophysiology are extremely complex and
make the use of the ABI in diabetics potentially problem-
atic.
It is possible that those individuals who had a baseline
ABI closer to the cut-points would be more likely to cross
the threshold value due to measurement error. To examine
this possibility, we determined the distribution of changes
in the ABI across the spectrum of normal baseline ABI
values. This analysis revealed that those who had a baseline
value at the extremes of the normal range were much more
likely to have a second ABI value that was closer to the
normal ABI (ie, regression to the mean). Therefore, for
values farther to the extremes of the normal ABI spectrum,
it appears random measurement error would have resulted
in a smaller probability for crossing a threshold. This,
combined with the high intraclass correlation for the mea-
surement of the ABI in MESA, argue against measurement
error being responsible for a significant proportion of sub-
jects progressing beyond the threshold values.
Strengths of this study include a large sample size that
includes ample representation of men and women, as well
as multiple ethnic groups. All subjects underwent a stan-
dardized examination procedure over multiple study visits
affording the opportunity to study prospective changes of
several study variables. There were many novel biomarkers
available for analysis. Finally, this study examined the asso-
ciations for an increase or decrease in the ABI and the
reproducibility of the ankle-brachial index was high. On the
other hand, within the context of changes in the ankle-
brachial index, this study is limited by a relatively short
follow-up period (average: 3 years) and the absolute num-
ber of subjects whomoved into the low or high ABI groups
was small. However, since individuals with a PAD are at
increased risk for incident CVD events in the relatively
short term, the findings presented here are of clinical rele-
vance. Also, there were approximately 900 subjects who did
not have a follow-up ABI. This group was older than
included participants but had lower levels of important risk
factors, suggesting our results are not likely biased. Finally,
the number of Chinese subjects in the low or high ABI
categories was relatively small likely leading to the lack of
significance for the associations in this ethnic group.
In conclusion, in this multi-ethnic cohort of men and
women from across the United States and over an average
of 3 years, age, hypertension, diabetes, pack-years of ciga-rette smoking, and higher homocysteine were associated
with developing an ABI 0.90, while male sex and increas-
ing body mass index were associated with an increase in the
ABI to  1.40. Importantly, African Americans had an
increased risk for developing an ABI  0.90 but a reduced
risk for developing an ABI  1.40. These results may
inform clinicians on characteristics in their patients that
may predispose them to developing peripheral arterial dis-
ease. Importantly, in exploratory analyses we found a sig-
nificant association between change in the ABI and inci-
dent coronary artery bypass graft and other (noncoronary)
revascularizations. Further work is warranted to confirm
these findings.
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Changes in the ankle-brachial index (ABI) and progression to
peripheral arterial disease (PAD) may result in major detrimental
effects on quality of life and functional status and, more impor-
tantly, are potent predictors of myocardial infarction, stroke, and
death. Despite its frequent occurrence, little is known about the
natural history of PAD among minority ethnic groups.
The Multi-Ethnic Study of Atherosclerosis (MESA) was de-
signed to determine ethnic differences in the progression of sub-
clinical to clinical cardiovascular disease.
In the current study, Allison et al assessed changes in ABI in
the MESA cohort over a 3-year time period. The authors conclude
that besides traditional risk factors, African Americans had a signif-
icantly higher risk of progression to a low ABI (0.9) and a
reduced trend towards progression to a high ABI (1.4). Con-
versely, Hispanics and Chinese did not reveal significant changes in
ABI over time. These findings should not come as a surprise as
African Americans have repeatedly been shown to have a higher
prevalence of PAD, which appears independent of both traditional
and novel vascular risk factors. There are, however, several uncer-
tainties and ambiguities that deserve further investigation.
Although PAD has traditionally been defined as resting ABI of
less than 0.90, the ABI may underestimate the severity of disease in
individuals with calcified, noncompressible arteries, which areadvanced age. Although the literature quoted by most epidemio-
logic studies, including this one, regarding the accuracy of the ABI
to detect PAD is primarily based in small clinical observational
studies that assessed individuals with established PAD prior to
treatment, the ABI has been accepted without adequate scrutiny in
all populations, including those with high prevalence of diabetes.
In the MESA cohort, Hispanics did not have an increased risk of
significant ABI changes despite similar age and sex-adjusted prev-
alence of baseline diabetes and dyslipidemia compared with African
Americans. Allison et al claim that the stability of ABI among
Hispanics may be related to either no actual changes or similar
progression in atherosclerosis and arterial rigidity. If one assumes
that, as suggested by the authors, progression is the rule, the lack of
changes in ABI may be more likely related to progression of both
atherosclerosis and arterial rigidity. It may also mean that among
Hispanics, there may be individuals with either baseline or subse-
quent stenosis of 50% or more in a major leg artery, ie, PAD, that
may not result in lower ABI because of the “compensatory”
increased arterial rigidity. The ABImay, therefore, be inaccurate to
detect PAD in Hispanics given their high prevalence of diabetes
and vascular calcification that render the ABI unreliable. Other
noninvasive tests, such as pulse volume recordings and toe-brachial
index, in addition to the ABI, should be assessed for accurate
detection and screening of PAD in this defined population.
